Thromboplastin

• 

  Subject Areas on Research

  • A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation. 
  • A c-Fos- and E1A-interacting component of the tissue factor basal promoter complex mediates synergistic activation of transcription by transforming growth factor-beta1. 
  • A cell-based model of thrombin generation. 
  • A model for the tissue factor pathway to thrombin. I. An empirical study. 
  • A possible mechanism of action of activated factor VII independent of tissue factor. 
  • A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes. 
  • A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. 
  • Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. 
  • Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. 
  • Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. 
  • Aminonaphthalenesulfonamides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes. 
  • An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. 
  • Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. 
  • Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. 
  • Blockade of tissue factor: treatment for organ injury in established sepsis. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Cellular interactions in hemostasis. 
  • Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. 
  • Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. 
  • Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. 
  • Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. 
  • Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. 
  • Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa. 
  • D-Dimer in African Americans: Whole Genome Sequence Analysis and Relationship to Cardiovascular Disease Risk in the Jackson Heart Study. 
  • Deencryption of cellular tissue factor is independent of its cytoplasmic domain. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. 
  • Disseminated intravascular coagulation (DIC): an approach. 
  • Dysregulation of hemostasis by cancer. 
  • Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. 
  • Extrinsic pathway proteolytic activity. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. 
  • Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. 
  • HIV envelope gp120 activates human arterial smooth muscle cells. 
  • Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. 
  • Hypercoagulable states in cardiovascular disease. 
  • Infant cardiopulmonary bypass: a procoagulant state. 
  • Inflammation does not predispose to bleeding in hemophilia. 
  • Ischemia/reperfusion injury in microvascular surgery. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. 
  • Monitoring warfarin therapy in patients with lupus anticoagulants. 
  • Newer concepts of blood coagulation. 
  • P-selectin induces the expression of tissue factor on monocytes. 
  • PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. 
  • Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. 
  • Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. 
  • Platelet activity of high-dose factor VIIa is independent of tissue factor. 
  • Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. 
  • Platelet procoagulant complex assembly in a tissue factor-initiated system. 
  • Platelet-dependent action of high-dose factor VIIa. 
  • Porcine endothelial cells cocultured with smooth muscle cells became procoagulant in vitro. 
  • Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. 
  • Rethinking the coagulation cascade. 
  • Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. 
  • Some things I thought I knew about tissue factor that turn out to be wrong. 
  • Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. 
  • Surface-dependent hemostasis. 
  • Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. 
  • The Tissue Factor Pathway and Wound Healing. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The coagulation cascade in cirrhosis. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. 
  • The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. 
  • The evaluation of complex-dependent alterations in human factor VIIa. 
  • The immune consequences of trauma. 
  • The multiple roles of tissue factor in wound healing. 
  • The next best thing in factor VIIa. 
  • The subunit structure of normal and hemophilic factor VIII. 
  • Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. 
  • Tissue factor and fibrin in tumor angiogenesis. 
  • Tissue factor around dermal vessels has bound factor VII in the absence of injury. 
  • Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. 
  • Tissue factor in brain is not saturated with factor VIIa: implications for factor VIIa dosing in intracerebral hemorrhage. 
  • Tissue factor in experimental acute lung injury. 
  • Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. 
  • Tissue factor, thrombin, and cancer. 
  • Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. 
  • Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. 
  • Variability in platelet procoagulant activity in healthy volunteers. 
  • Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. 
  • Wound healing in hemophilia B mice and low tissue factor mice. 
  • [Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor of Otolaryngology, Head and Neck Surgery & Communication Sciences